via University of York
An international team of scientists have discovered a molecule which prevents tumour cells spreading from a primary cancer site to colonise other sites in the body.
The multidisciplinary research team, from the University of York, Leiden University and Technion (Israel Institute of Technology) discovered that the small, sugar-like molecule maintains the integrity of tissue around a tumour during cancer. They have shown the sugar-like molecules markedly reduce cancer spread in mice, paving the way for development towards clinical application.
Metastasis, the spread of cancer cells to distant sites in the body, is what makes cancer so lethal. Metastasis formation depends on the ability of cancer cells to detach from the primary tumour site, and invade through blood vessel walls and tissue barriers to reach secondary sites of growth. This metastatic invasion process requires biological molecules called enzymes, which digest proteins and sugars in the space around cells, enabling cancer cells to pass through the subsequent gaps.
One abundant class of sugar that surrounds cells are the heparan sulfates, which are long chain-like molecules that help stabilise the integrity of the extracellular space. Heparan sulfate sugars are digested by an enzyme called heparanase, which acts to chop up the ‘chains’ and thereby weaken the space around cells.
Metastatic cancer cells produce large amounts of heparanase enzyme, which helps them to spread around the body. Inhibiting heparanase is therefore a major target for anti-cancer therapy.
The researchers developed and tested a new sugar-like molecular that reacts with the enzyme heparanase, whose 3-D structure was first solved by the York group. Once the new molecule is bound, the heparanase enzyme is unable to bind or cut heparin sugar chains around cells. In this way, the tissue around cells remains firm and inaccessible to dislodged cells.
At York, Professor Gideon Davies and Dr Liang Wu from the Department of Chemistry showed how the enzyme inhibitor inhibits heparanase. The research team is now looking at how the molecule can be further improved.
Professor Davies said: “It has been brilliant to see the work develop from fundamental studies of enzyme structure and function and evolve into small molecules with potent anti-cancer activities. It is really exciting”
Researchers at Technion studied the new molecule in mouse models of lung cancer, breast cancer and blood cancer. While it is still too early to determine whether the new molecule will reach clinical application, the results are promising and the institutes involved have already applied for a patent on the molecule.
Lead author of the study Professor Hermen Overkleeft from Leiden University said: “Now we have to find out whether the compound is stable, safe for the human body, ends up in the right place in sufficient quantities, and so on. That takes a couple of years, it may come to nothing and someone has to be willing to take that financial risk.
“Our molecule is one of the few agents that can inhibit heparanase tightly and specifically. Medicine has a preference for small, simple molecules like this.”
Original Article: Chemists create molecule that prevents tumour cells from spreading
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Strategy could remove metastatic traits and drug resistance from lung cancer cells
A research team led by Professor Kwang-Hyun Cho from the Department of Bio and Brain Engineering at KAIST succeeded in using systems biology research to change the properties of carcinogenic cells in ...
- 2023 Brain Metastasis Therapeutic Market: New Research Report with Worldwide Top Players, Major Regions
Get a sample PDF of the report at Key player companies in global Brain Metastasis Therapeutic Market are: The report providing scenario of history and present performance with an overview of ...
- Israeli Cancer Breakthrough: New molecular blocker halts breast cancer metastasis
A combination of cellular biology and structural biology advances the fight against breast cancer in a way never before possible.
- Revealing the Molecules Underlying Metastasis
Some studies have suggested that in some cancers, like melanoma, fewer than 0.1 percent of tumor cells metastasize. But metastasis has been blamed for 90 percent of cancer deaths. As such, scientists ...
- Bone Metastasis Treatment Market Share, Analysis, Size, Prominent Players, and Forecast 2028
Bone metastasis refers to a form of cancer in which cancer cells from other areas of the body cause bone cancer.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”metastasis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- CRISPR Knockout Identifies New Biomarkers for PARP Inhibitor Resistance in Prostate Cancer
Two PARP inhibitors—olaparib (Lynparza) and rucaparib (Rubraca)—have been approved by the FDA to treat metastatic castration-resistant prostate cancer (mCRPC), and the data from the trials for ...
- Quince Therapeutics Shares Jump 65% After Sale of Protease Inhibitor Portfolio
Quince Therapeutics Inc. shares were up 65% at $1.33 after the company said it sold its legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals Inc. Lighthouse Pharma is ...
- Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
The 6th Annual DDR Inhibitors Summit, held in Boston January 24-26, 2023, brought together academic and pharmaceutical industry researchers to share progress across the preclinical and clinical ...
- MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
Overall, the oral murine double minute-2 (MDM2) inhibitor milademetan produced a disease control rate (DCR) of 45.8% in 107 patients, including 58.5% in a subgroup with dedifferentiated ...
- SGLT2 inhibitor found to reduce endothelial dysfunction associated with ALDH2 alcohol face flushing variant
Citation: SGLT2 inhibitor found to reduce endothelial dysfunction associated with ALDH2 alcohol face flushing variant (2023, January 26) retrieved 28 January 2023 from https://medicalxpress.com ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”inhibiting heparanase” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]